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Two Pediatric Osteosarcoma Cases with Delayed
Methotrexate Excretion: Its Clinical Course and
Management 
Introduction
High-dose methotrexate (HD MTX) is a major chemotherapeutic
agent that is used for the treatment of osteosarcoma [1]. Individual mo-
nitoring of the methotrexate (MTX) serum levels enables appropriate
alterations of the leucovorin dosage and this can help avoid potential
life-threatening toxicities [2]. For example, without leucovorin rescue
based on MTX serum level monitoring, the mortality rates due to se-
rious complication range from 4.6% to 6% [2]. 
Nevertheless, serious adverse events still occur because of de-
layed MTX excretion. Hemodialysis, hemoperfusion and peritoneal
dialysis have all been attempted, but these procedures place cancer
patients at risk of other serious complications such as bleeding or
infection [3]. Carboxypetidase G2 (CPDG2) shows promise as a
means of increasing MTX excretion and a clinical trial for it is
underway [4]. However, as yet the safety data has not been made
available, and especially for children. 
For this reason, the treatment of patients with delayed MTX
excretion inevitably depends largely on supportive measures. We
report here on two cases of pediatric osteosarcoma in whom the
delayed MTX excretion was managed using supportive measures.
MTX excretion was promoted in these patients without having to
adopt invasive procedures, and any potential life-threatening
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High-dose methotrexate (MTX) chemotherapy extends the duration of hospitalization and
introduces the risks of serious complications related to delayed MTX excretion. The
treatment of delayed MTX excretion is largely dependent on invasive measures such as
hemodialysis because the clinical data regarding the efficacy or safety of carboxypetidase
G2 is limited. We report here on the cases of two pediatric osteosarcoma patients with
delayed MTX excretion and who were successfully managed using supportive measures.
Potential life-threatening complications were prevented by administering high doses of
leucovorin.
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Case Report
1 Case 1 
A 4-year-old boy was diagnosed as having osteosarcoma of the
left proximal humerus. His laboratory test results, including the
serum creatinine and creatinine clearance, were all in the normal
range. His first course of HD MTX was administered at 12 g/m
2.
One hour before MTX infusion, he was intravenously hydrated with
250 mL/m
2 of 5% glucose together with containing 100 mol/L
NaHCO3 and 20 mL KCl solution. The MTX was dissolved in 500
mL of D5W and infused over 4 hours. After this MTX infusion, he
was hydrated with the same fluid to a total of 1,500 mL/m
2 during
the first 24 hours. His 4-hour MTX level was 1,522 μ mol/L, and he
suffered from mild nausea. His oral intake was moderate and the
urine volume was maintained at above 1,750 mL/day. The fol-
lowing day, he had gained 1.2 kg in weight (range, 19.4 to 20.6 kg),
and he complained of abdominal pain, nausea and vomiting. His 24-
hour MTX level was 781 μ mol/L, and thus, leucovorin was
immediately escalated to 1,000 mg/m
2 and administered every 3
hours. His serum creatinine level increased up to 2 mg/dL, but his
urine output was maintained at above 50 mL/m
2/hr without diu-
retics. He suffered oral mucositis (grade III), and yet he did not ex-
perience any diarrhea, fever or leukopenia. Over the following
hospital days, his MTX level decreased very slowly and finally it
reached to 0.10 μ mol/L 10 days after high dose leucovorin rescue
(Fig. 1). Following recovery, he proceeded to chemotherapy com-
prised of cisplatin (100 mg/m
2) and doxorubicin (60 mg/m
2). The
second course of chemotherapy was comprised of a reduced MTX
dose (6 g/m
2), cisplatin (100 mg/m
2) and doxorubicin (60 mg/m
2),
and it was completed uneventfully. After surgery, he had received
all the scheduled chemotherapy, with the full dose of MTX (12
g/m
2). He did not suffer any renal complication during postoperative
chemotherapy and at present, he has been continuously disease free
for 5 years. 
2 Case 2
A 7-year-old girl with osteosarcoma of the right distal femur
received HD MTX (12 g/m
2). She had previously undergone four
courses of HD MTX uneventfully at another institution. The labo-
ratory tests revealed asymptomatic microscopic hematuria, and yet
her renal function (serum creatinine and creatinine clearance) was
normal. She had not been administered any other nephrotoxic agent,
such as cisplatin or ifosfamide. HD MTX was administered as
described in case 1. During four hours of MTX administration, she
suffered nausea and vomiting and the estimated amount of vomitus
was about 150 mL. Her MTX level (4-hour) peaked at 1,630 μ mol/L.
Over the following 20 hours, she continuously suffered from nausea
and vomiting. Her 24-hour MTX level was 892 μ mol/L and leuco-
vorin was immediately escalated to 1,000 mg/m
2 and administered
every 3 hours. Her urine output slowly began to decrease and her
serum creatinine level increased from 0.4 mg/dL to 1.8 mg/dL (Fig. 2).
Diuretics were administered to maintain a urine output of above 50
mL/m
2/hr. She complained of abdominal pain, nausea and ex-
perienced several episodes of vomiting. However, she did not ex-
perience any mucositis, diarrhea or leukopenia. Her serum MTX le-
vel decreased slowly, but it finally reached 0.13 μ mol/L on the 16th
day (384 hours after HD MTX administration). Upon recovery, she
proceeded to surgery because her tumor size was increasing. Due to
the poor response to preoperative chemotherapy, her postoperative
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Fig. 1. Correlation between the serum methotrexate (MTX) level
and the serum creatinine level in the patient of case 1.
4
2,500
240
(hr)
0
MTX
MTX
(
mol/L)

Cr
Cr
(mg/dL)
192
144
120
96
72
48
24
2,000
1,500
1,000
500
216
168
2.5
0
2.0
1.5
1.0
0.5
264
Fig. 2. Correlation between the serum methotrexate (MTX) level
and the serum creatinine level in the patient of case 2. chemotherapy was modified to the regimen comprised of cisplatin
(100 mg/m
2), doxorubicin (60 mg/m
2), ifosfamide (14 g/m
2) and
bleomycin (30 mg/m
2). At present, she has been continuously
disease free for 6 years and is still suffering from intermittent
hematuria. 
Discussion 
To the best of our knowledge, our two cases are the youngest
reported cases of delayed MTX excretion. Both patients were
successfully managed using supportive measures. However, the
factors that predisposed the patients to delayed MTX excretion were
unclear in these cases. A reduced effective blood volume or the con-
current use of nephrotoxic agents are known to be related to the de-
velopment of delayed MTX excretion [5,6], but neither patient had
signs of decreased blood volume nor they were concurrently recei-
ving any nephrotoxic agent [7]. Furthermore, the previous courses
of HD MTX in case 2 and the following chemotherapy (case 1)
were uneventful. 
The pharmacokinetics of HD MTX shows individual variability
[8]. After administration when the renal function is normal, more
than 90% of the MTX administered combines with albumin and it is
excreted to the urine within 12 hours [9]. The excretion of MTX is
influenced by many factors such as age, the hydration status and the
concurrent use of nephrotoxic agents [2]. Furthermore, it has been
reported that delayed MTX excretion may occur in the absence of
any predisposing factor [5,10,11], and in our cases, the reason for
delayed MTX excretion was not determined. However, we surmise
that a young age or a small body size might have contributed to its
development. Given a low body weight, a poor oral intake or severe
vomiting during MTX infusion could lead to volume depletion,
even with intravenous hydration. 
In the past, delayed MTX excretion was largely treated using
supportive measures; the key element of which was to increase the
leucovorin dosage [2]. However, concern exists that elevated leuco-
vorin dosages might compromise the antitumor effect of MTX [12].
The serum level of MTX is supposed to reflect the drug concen-
tration in tumor cells, and if leucovorin is administered at elevated
dosages, there is a possibility that tumor cells might be rescued.
Meyers et al. [12] found that the survival of osteosarcoma patients
treated with the Children’s Cancer Study Group 782 protocol was
poorer than that of those treated with the T10 protocol of the Me-
morial Sloan-Kettering Cancer Center, and they suggested that this
might be attributable to the different leucovorin dosages that were
administered. On the other hand, it has been reported the expression
profiles of reduced folate carrier in normal somatic cells and tumor
cells differ, and that as a result, leucovorin targets the normal cells
[1]. However, further studies are needed to clarify the effect of
leucovorin on tumor cells.
Hemodialysis has been attempted in cases of delayed MTX
excretion that fail to respond to supportive measures [13]. However,
controversy exists regarding the efficacies of hemodialysis and
hemoperfusion. In one literature study, single remedy conventional
hemodialysis lowered the serum MTX levels by about 52%, but it
took 14 days to achieve complete MTX excretion [2]. Furthermore,
it has been reported that high-flux hemodialysis is more effective
and removes more MTX than conventional hemodialysis (75.7% vs.
52%) over a shorter period of time (4 hours vs. 14 days) [13-15].
However, rebound remains a problem [2], and the invasive nature of
catheter placement may place cancer patients at risk for com-
plications such as bleeding or infection [3].
Various pharmacotherapies have been developed and im-
plemented in cases of delayed MTX excretion. Thymidine directly
inhibits the action of MTX, but the continuous infusion of high
doses is required because of its short half life [11]. CPDG2 is con-
sidered a promising agent that inactivates MTX by hydrolyzing the
glutamic acid located at its C-terminal [4]. In one study in twenty-
one cancer patients with delayed MTX excretion, CPDG2 reduced
the serum MTX levels by 98% within 15 minutes, without any se-
rious adverse reaction [14]. Clinical trials are currently underway
[4], and it is hoped that this development will lead to the im-
plementation of HD MTX chemotherapy in an ambulatory setting,
which would substantially reduce medical costs.
In conclusion, two pediatric osteosarcoma patients with delayed
MTX excretion were successfully managed using supportive
measures without any invasive procedure. Potential life-threatening
complications were prevented by administering leucovorin at high
dosages. Currently, HD MTX chemotherapy requires an extended
period of hospitalization and presents the risks of serious com-
plications related to delayed excretion. It is hoped that in the future,
CPDG2 will be used to treat patients with delayed MTX excretion
and enable HD MTX chemotherapy to be performed on an
ambulatory basis.
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